What's considered excellent revenue growth depends on the industry. For pharmaceutical companies, especially those with a ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Editas Medicine (EDIT – Research Report) yesterday and set a price target of ...

On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vi ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

On track to declare two in vivo editingdevelopment candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...